Physician profile
Fazal Bari
NPI 1407965775
$11,567.17
in general payments reported to CMS, 2019-2025
71 companies · $1,423 in 2025
The $1,423 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,658 · 2020: $1,657 · 2021: $1,501 · 2022: $1,462 · 2023: $1,417 · 2024: $1,449 · 2025: $1,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,288.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,185.44 | 2019-2025 | Lynparza, Enhertu, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $809.24 | 2019-2025 | Opdivo, Opdualag |
| Amgen INC. | $793.23 | 2019-2024 | Lumakras, Kyprolis, Blincyto |
| Janssen Biotech, INC. | $793.05 | 2019-2025 | Akeega, Erleada, Balversa |
| Novartis Pharmaceuticals Corporation | $705.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $587.15 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Daiichi Sankyo INC. | $568.37 | 2020-2025 | Enhertu, Injectafer |
| Incyte Corporation | $493.01 | 2019-2025 | Jakafi |
| Seagen INC. | $439.77 | 2019-2023 | Adcetris, Padcev, Tukysa |
| Glaxosmithkline, LLC. | $433.14 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Ferring Pharmaceuticals INC. | $367.43 | 2024-2025 | Rebyota |
| Karyopharm Therapeutics INC. | $338.40 | 2020-2024 | Xpovio |
| Genzyme Corporation | $221.95 | 2019-2025 | |
| Astellas Pharma US INC | $216.17 | 2019-2025 | Vyloy, Padcev |
| Regeneron Healthcare Solutions, INC. | $207.10 | 2019-2025 | Libtayo |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fazal Bari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.